 ISFIYA, Israel, July 9, 2019 PRNewswire -- Check-Cap Ltd. the Company or Check-Cap CHEK NASDAQ:CHEKW, NASDAQ:CHEKZ, a clinical stage medical diagnostics company advancing the development of C-Scan, the first and only preparation-free capsule based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system. The study included 90 evaluable patients who either had known polyps or were considered to be of average risk. 